AI assistant
Vitrolife — Board/Management Information 2025
Apr 10, 2025
2989_rns_2025-04-10_05eed1db-48d2-4b09-9c3e-12c8fb7d9e64.pdf
Board/Management Information
Open in viewerOpens in your device viewer
VITROLIFE GROUP™
The Vitrolife Group appoints Pär Ihrskog as the new Chief Financial Officer
Pär Ihrskog has been appointed CFO of the Vitrolife Group effective 10 October 2025. Pär currently serves as CFO at Bufab Group and brings a wealth of experience to the company, having also served as Group CFO/CIO at Embellence Group. He spent the majority of his career working in finance roles, of increasing seniority in SKF, also living and working in several countries, including the U.S. and China. Pär holds a master’s degree in business administration.
“We are delighted to welcome Pär Ihrskog to the Vitrolife Group as CFO. His extensive financial expertise, combined with a proven track record of leadership in listed companies, brings valuable strategic and operational insight that will support the company in driving sustainable profitable growth,” says Bronwyn Brophy O’Connor, CEO.
Helena Wennerström will remain as acting CFO until Pär takes office.
Gothenburg, 10 April 2025
VITROLIFE AB (publ)
Bronwyn Brophy O’Connor, CEO
The information was submitted for publication, through the agency of the contact persons set out above, at 10-04-2025 12:00 CET.
Contact:
Amelie Wilson, Investor Relations, [email protected]
This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.
Vitrolife Group is a global provider of medical devices and genetic testing solutions. Our vision is to enable people to fulfil the dream of having a healthy baby. Our mission is to be the leading global partner in reproductive health, striving for better treatment outcomes for patients. With 1,100 employees worldwide and headquarters in Gothenburg, Sweden, our products and services are available in over 125 countries through our direct presence and a network of distributors. Vitrolife AB (publ) is listed on Nasdaq Stockholm.
Vitrolife AB (publ), Box 9080, SE-400 92 Gothenburg, Sweden. Corporate identity number 556354-3452. Tel: +46 31 721 80 00. E-mail: [email protected]. Website: www.vitrolifegroup.com.